Natriuretic Effect of Two Weeks of Dapagliflozin Treatment in Patients With Type 2 Diabetes and Preserved Kidney Function During Standardized Sodium Intake: Results of the DAPASALT Trial

OBJECTIVE: Sodium–glucose cotransporter 2 (SGLT2) inhibitors reduce the risk for heart failure hospitalization potentially by inducing sodium excretion, osmotic diuresis, and plasma volume contraction. Few studies have investigated this hypothesis, but none have assessed cumulative sodium excretion...

Descripción completa

Detalles Bibliográficos
Autores principales: Scholtes, Rosalie A., Muskiet, Marcel H.A., van Baar, Michiel J.B., Hesp, Anne C., Greasley, Peter J., Karlsson, Cecilia, Hammarstedt, Ann, Arya, Niki, van Raalte, Daniël H., Heerspink, Hiddo J.L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Diabetes Association 2021
Materias:
Emerging Therapies: Drugs and Regimens
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818331/
https://www.ncbi.nlm.nih.gov/pubmed/33318125
http://dx.doi.org/10.2337/dc20-2604

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7818331/
https://www.ncbi.nlm.nih.gov/pubmed/33318125
http://dx.doi.org/10.2337/dc20-2604

Ejemplares similares